Elsevier

Transplantation Proceedings

Volume 42, Issue 10, December 2010, Pages 4072-4073
Transplantation Proceedings

Renal transplantation
Complications: Metabolic
Risk Factors for the Development of New-Onset Diabetes Mellitus in a Living Related Renal Transplant Program

https://doi.org/10.1016/j.transproceed.2010.10.008Get rights and content

Abstract

New-onset diabetes mellitus is associated with considerable morbidity after transplantation. We evaluated 78 living related renal transplant recipients due to all causes except diabetic nephropathy a waiting a living related renal transplantation. We evaluated demographic characteristics, pretransplant glycemic profile, fasting C-peptide levels, plasma insulin levels, pretransplant insulin resistance, and immunosuppression protocols. Among the 16.7% of patients developing diabetes mellitus at the end of 1 year, age, family history, and impaired glucose tolerance at the time of transplantation corelated with the development of diabetes mellitus in the posttransplant period.

Section snippets

Materials and Methods

We examined 78 adult end-stage renal disease patients due to all causes except diabetic nephropathy, who were on the waiting list for a first live related renal transplantation. Our primary aim of the study was to correlate the incidence of NODM with pretransplant glycemic profiles, fasting plasma C-peptide levels, plasma insulin levels, and pretransplant insulin resistance. An oral glucose tolerance test (OGTT) was performed both pre as well as 1, 3, 6 and 12 months posttransplantation.

Results

The mean age of study recipients was 32.4 years, including 65.4% below and 34.6% above 40 years of age. There were 65 males and 13 female recipients (M:F = 5:1). Sixteen patients (20.4%) were hepatitis C virus (HCV) positive before transplantation. The most common blood groups were group B (41%) and group O (26.9%) with group A (17.9%) and group AB (14.1%) constituting the other cases.

The mean age of the living donors was 43.03 years, including 37.2% below and 62.8% above 40 years of age. Most

Discussion

The development of NODM is a well-known complication in renal transplant patients with an incidences of 2% to 50% reported in various studies.3, 4, 5 Most patients develop NODM within the early postoperative months.5 In the present study, we observed an NODM incidence of 16.7% using the ADA criteria,7 a figure that is consistent with the literature.5 A previous study from our institute by Saxena et al8 performed between 1978 and 1992 reported a much lower (4.8%) incidence of NODM. However,

References (12)

There are more references available in the full text version of this article.

Cited by (10)

  • An observational prospective study to evaluate the outcomes of new onset diabetes after renal transplantation (NODAT) in a tertiary care centre in eastern India

    2020, Diabetes Research and Clinical Practice
    Citation Excerpt :

    In a study conducted by Valderhaug TG et al., post-transplant diabetes mellitus (PTDM) was reported in 14% patients [16]. In Indian studies, the incidences of NODAT were 19.12%, 16.75% and 54.5% in studies conducted by Prakash J et al., Sharma A et al., and Bora GS et al respectively [17–19]. So there has been wide variation among incidence and in our study, the incidence of NODAT is 24%.

  • A novel mechanism of pre-transplant insulin resistance contributing to post-transplant complications: Cyclosporin A-induced O-GlcNAcylation

    2017, Biochemical and Biophysical Research Communications
    Citation Excerpt :

    Tokodai et al. demonstrate that insulin resistance, as judged by homeostasis model assessment for insulin resistance (HOMA-IR), acts as a risk factor for new-onset diabetes after transplantation (NODAT) [4]. Moreover, several clinical studies also show that pre-transplant glucose intolerance is an independent predictor of NODAT [5–8]. However, the underlying mechanism behind this is less investigated.

  • The incidence of new onset diabetes after transplantation and related factors: Single center experience

    2017, Nefrologia
    Citation Excerpt :

    This suggests that diabetogenic effect of tacrolimus is dose dependent.49 However, in some studies, authors did not observe any association between tacrolimus and PTDM.50,51 In our study, there was no significant difference between tacrolimus and cyclosporine.

  • Post-transplant diabetes mellitus: Is it associated with poor allograft outcomes in renal transplants?

    2013, Transplantation Proceedings
    Citation Excerpt :

    The incidence of infection, acute rejection, and delayed graft function were related to the intensity and type of immunosuppressant used. Tacrolimus was more diabetogenic than CsA, and, in the ELITE (Efficacy Limiting Toxicity Elimination)- Symphony study in which a similar mycophenolate mofetil dose was administered in combination with standard or low doses of calcineurin inhibitors (CsA and tacrolimus), bacterial and viral infections were more common with the standard dose of cyclosporine.21 In our study, the levels of tadrolimus and CsA used were above their therapeutic ranges.

  • Post-transplant Diabetes Mellitus: What Physicians Need to Know

    2022, Journal of Association of Physicians of India
View all citing articles on Scopus
View full text